Aberrant cytokine production in CD45. 2-mutant and CD45

Slides:

Advertisements

Similar presentations

Neoplastic blood cells become pluripotent

Advertisements

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

CD25 expression is associated with unfavorable clinical outcome.

by Shawn W. Cochrane, Ying Zhao, Robert S. Welner, and Xiao-Hong Sun

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

by Giridharan Ramsingh, Meagan A. Jacoby, Jin Shao, Rigoberto E

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets by Maria Nikolova, Jean-Daniel Lelievre, Matthieu.

Both haematopoietic and non‐haematopoietic compartments are involved in myocarditis development.A.Kaplan‐Meier survival curves showing survival of bone.

Figure 6 Lack of IRF5 causes a reduction in neutrophil influx

Volume 4, Issue 1, Pages (January 2015)

Functions of myeloid cells.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis Kais Hussein, Angelika.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.

AG-221 can reduce intracellular 2HG levels and induce differentiation in primary human IDH2R140Q- or IDH2R172K-mutant AML patient samples treated ex vivo.

The Expression of Th17-Associated Cytokines in Human Acute Graft-versus-Host Disease Yuejun Liu, Yifeng Cai, Lan Dai, Guanghua Chen, Xiao Ma, Ying Wang,

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

Fig. 4 PD-L1 expression is found in the spleen and the BM of mice transplanted with JAK2V617F-transduced bone marrow. PD-L1 expression is found in the.

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Kinetics of clone appearance, size, persistence, and lineage content.

Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression The N:M ratio is significantly increased.

Setdb1 has cell-intrinsic functions in B cell development.

Analysis of peripheral blood CD4+CD25+ T-cells after B6

α-Cells mainly express SSTR2 and SSTR3

Comparison of conventional NSG and hIL-7 expressing NSG humanized mice

Relationship between blood cell and plasma miRNA expression among published circulating cancer biomarkers. Relationship between blood cell and plasma miRNA.

Characteristics of GM-CSF–secreting CD4+ T cells.

Anti-PD-1H Antibody Prevents Graft Versus Host Disease

Cytokine profiles can predict severe CRS

Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.

C-MYC controls expression of ABC drug transporters in CD34+ hematopoietic progenitors. c-MYC controls expression of ABC drug transporters in CD34+ hematopoietic.

Leukemic blasts express a “hypoxia signature

Effect of HA on hematopoietic recovery in tumor-bearing mice.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

GS87 demonstrates efficacy in a circulating AML mouse model system.

CD11bhighCD27high conventional NK cells are converted into MDSCs

Fig. 4 PD-L1 expression is found in the spleen and the BM of mice transplanted with JAK2V617F-transduced bone marrow. PD-L1 expression is found in the.

Frequent alterations identified and potential actionability.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

JAK2V617F leads to increased 5-hmC and genome-wide loss of cytosine methylation in primary patient samples. JAK2V617F leads to increased 5-hmC and genome-wide.

Kinetic of NFAT-CBR expression.

pDCs from the melanoma environment responded to TLR-L stimulation.

JAK2V617F leads to 5-hmC gain in vivo that correlates with gene expression. JAK2V617F leads to 5-hmC gain in vivo that correlates with gene expression.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

AMs contribute to the progression of EGFR-mutant lung adenocarcinoma.

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

GM-CSF is required for CA-MSC–induced tumor metastasis.

CA-MSCs differentially secrete GM-CSF.

SY-1425 induces maturation in RARA-high AML

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Measurements of the apoptotic response of CLL cells to radiation and the association with elevated genomic complexity. Measurements of the apoptotic response.

Loss of polarity gene Dlg1 leads to an expansion of C'-1 stage cells during pre-B cell differentiation. Loss of polarity gene Dlg1 leads to an expansion.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

An isogenic cell line screen reveals genomic drivers of drug response.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Comparison of MLTC responses to tumor/peptide stimuli at day 18 and day 34 of growth. Comparison of MLTC responses to tumor/peptide stimuli at day 18 and.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Presentation transcript:

Aberrant cytokine production in CD45. 2-mutant and CD45 Aberrant cytokine production in CD45.2-mutant and CD45.1-nonmutant cells from JAK2V617F-diseased mice. Aberrant cytokine production in CD45.2-mutant and CD45.1-nonmutant cells from JAK2V617F-diseased mice. A, schematic illustration of bone marrow transplantation experiments using Jak2V617F;Vav-Cre knockin mice (CD45.2) as donors. B, single-cell analysis of sorted mutant (CD45.2) and nonmutant (CD45.1) populations from Jak2V617F-mutant diseased mice (J2VF) and transplanted healthy controls (Ctrl). Percentages of cytokine secreting cells are shown above. C, cytokine expression levels of sorted CD45.1-positive and CD45.1-negative myelofibrosis and Vav-Cre–negative control cells relative to CD45.1 control cells. D, pie charts displaying the percentage of sorted mutant (CD45.2) and nonmutant (CD45.1) secreting different numbers of cytokines (0, 1, 2, 3, 4, 5+). E, cytokine secretion data showing that 59.3% of human PMF cells (patient PMF#11, allele burden: 38%) secrete at least one cytokine. F, pie charts depicting the percentage of human PMF cells and control cells secreting different numbers of cytokines (0, 1, 2, 3, 4+). Maria Kleppe et al. Cancer Discovery 2015;5:316-331 ©2015 by American Association for Cancer Research